Clinical Trial Update: Vorasidenib Maintenance for IDH Mutant Astrocytoma [Phase 3]

View source ↗

Summary

Phase 3 trial of vorasidenib maintenance for IDH-mutant Grade 2 or 3 astrocytoma is currently recruiting. The study is sponsored by the European Organisation fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idh-mutant Astrocytoma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: IDH-mutant Grade 2 or 3 Astrocytoma | Phase 3 | Status: RECRUITING